Endocrine Abstracts

The effects of conventional somatostatin analog (SSA) regimens on glucose homeostasis seem to have minor clinical impact in acromegaly. Recently, we performed a trial showing that high dose octreotide LAR significantly reduces IGF1 in acromegalic patients uncontrolled with conventional SSA doses. In this post-hoc analysis, we evaluated the effects of high doses versus high frequency octreotide LAR on glucose homeostasis (HbA1c, FPG, HOMA-R) in patients with acromegaly e...

Objective: In acromegaly, 25–50% of patients remain uncontrolled with conventional somatostatin analogue (SA) therapy. Evidence suggests that response may be improved by increasing the dose or frequency of administration of SAs. This study evaluated the efficacy and safety of octreotide LAR administered at a high dose or high frequency in patients with acromegaly.Methods: This was a 24-week prospective, multicenter, randomized, open-label trial in p...

Introduction: While searching for mechanisms contributing to the increased mortality of acromegaly, we have previously described an unexpected sympathoinhibition in newly diagnosed patients (Seravalle et al., Clin Endocrinol 77:262, 2012) and interpreted this finding as an adaptive phenomenon. It has also been shown that centrally administered somatostatin (SS) inhibits peripheral sympathetic outflow in rodents (Rettig et al., Am J Physiol 257:R588, 1989). Ba...